The Arab Drug Company (EGX:ADCI)
Egypt · Delayed Price · Currency is EGP 160.48
+1.79 (1.13%)
At close: Feb 2, 2026
The Arab Drug Company Income Statement
Financials in millions EGP. Fiscal year is July - June.
Millions EGP. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 1,188 | 1,115 | 784.65 | 630.1 | 503.79 | 537.05 |
Other Revenue | 2.75 | 2.75 | 0.88 | 3.64 | 1.25 | - |
| 1,191 | 1,118 | 785.52 | 633.73 | 505.04 | 537.05 | |
Revenue Growth (YoY) | 43.89% | 42.35% | 23.95% | 25.48% | -5.96% | 3.12% |
Cost of Revenue | 694.86 | 651.9 | 519.53 | 409.39 | 319.61 | 306.74 |
Gross Profit | 496.01 | 466.28 | 265.99 | 224.35 | 185.43 | 230.3 |
Selling, General & Admin | 118.62 | 117.58 | 98.14 | 98.83 | 81.02 | 81.78 |
Other Operating Expenses | 21.48 | 36.82 | 49.75 | 28.44 | 13.64 | 26.33 |
Operating Expenses | 140.1 | 154.41 | 147.89 | 127.27 | 94.66 | 108.11 |
Operating Income | 355.91 | 311.87 | 118.1 | 97.08 | 90.77 | 122.2 |
Interest Expense | -52.25 | -48.57 | -23.09 | -2.32 | -0.95 | -0.04 |
Interest & Investment Income | 11.87 | 19.3 | 27.98 | 1.11 | 1.67 | 4.4 |
Currency Exchange Gain (Loss) | -1.45 | -0.2 | 6.24 | 9.75 | 3.24 | 0.09 |
Other Non Operating Income (Expenses) | 14.08 | 12.41 | 3.17 | 1.11 | 3.05 | 4.29 |
EBT Excluding Unusual Items | 328.16 | 294.8 | 132.4 | 106.73 | 97.78 | 130.94 |
Gain (Loss) on Sale of Assets | - | - | 0.18 | - | 0.51 | 0.01 |
Pretax Income | 328.16 | 294.8 | 132.58 | 106.73 | 98.3 | 130.96 |
Income Tax Expense | 74.6 | 66.95 | 29.75 | 23.96 | 22 | 29.55 |
Net Income | 253.56 | 227.86 | 102.82 | 82.77 | 76.3 | 101.41 |
Preferred Dividends & Other Adjustments | 31.51 | 28.92 | 14.48 | 11.64 | - | - |
Net Income to Common | 222.05 | 198.93 | 88.35 | 71.13 | 76.3 | 101.41 |
Net Income Growth | 126.96% | 121.60% | 24.23% | 8.48% | -24.76% | 9.28% |
Shares Outstanding (Basic) | 12 | 12 | 12 | 12 | 14 | 14 |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 12 | 14 | 14 |
Shares Change (YoY) | -3.98% | - | - | -11.45% | -2.11% | -6.76% |
EPS (Basic) | 18.50 | 16.58 | 7.36 | 5.93 | 5.63 | 7.33 |
EPS (Diluted) | 18.50 | 16.58 | 7.36 | 5.93 | 5.63 | 7.33 |
EPS Growth | 127.84% | 125.18% | 24.21% | 5.28% | -23.14% | 17.20% |
Free Cash Flow | 70.02 | -0.38 | -83.19 | 24.33 | -57.04 | 7.71 |
Free Cash Flow Per Share | 5.83 | -0.03 | -6.93 | 2.03 | -4.21 | 0.56 |
Dividend Per Share | 4.167 | 4.167 | 4.175 | 2.250 | 2.400 | 2.500 |
Dividend Growth | -0.20% | -0.20% | 85.56% | -6.25% | -4.00% | 100.00% |
Gross Margin | 41.65% | 41.70% | 33.86% | 35.40% | 36.72% | 42.88% |
Operating Margin | 29.89% | 27.89% | 15.04% | 15.32% | 17.97% | 22.75% |
Profit Margin | 18.65% | 17.79% | 11.25% | 11.22% | 15.11% | 18.88% |
Free Cash Flow Margin | 5.88% | -0.03% | -10.59% | 3.84% | -11.29% | 1.44% |
EBITDA | 25,725 | 25,672 | 120.58 | 99.46 | 100.17 | 130.01 |
EBITDA Margin | 2160.17% | 2295.87% | 15.35% | 15.69% | 19.83% | 24.21% |
D&A For EBITDA | 25,369 | 25,360 | 2.48 | 2.38 | 9.39 | 7.81 |
EBIT | 355.91 | 311.87 | 118.1 | 97.08 | 90.77 | 122.2 |
EBIT Margin | 29.89% | 27.89% | 15.04% | 15.32% | 17.97% | 22.75% |
Effective Tax Rate | 22.73% | 22.71% | 22.44% | 22.45% | 22.38% | 22.56% |
Revenue as Reported | 1,191 | 1,118 | 785.52 | 633.73 | 505.04 | 537.05 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.